Status:
COMPLETED
A Study To Measure The Level Of Drug In Nasal Tissue And Blood After Taking A Single 2g Dose Or 500mg Tablets For Up To
Lead Sponsor:
Pfizer
Conditions:
Sinusitis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To measure the level of drug in nasal tissue and blood after taking a single 2g dose or 500mg tablets for up to 3 days.
Eligibility Criteria
Inclusion
- Subjects considered by the Principal Investigator as an appropriate candidate for endoscopic sinus surgery, e.g., for the removal of the thickened and diseased mucosal tissue that blocks the ostiomeatal complex (OMC).
Exclusion
- Known or suspected hypersensitivity or intolerance to any macrolide-like compound, including erythromycin, clarithromycin, azithromycin or telithromycin.
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2006
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT00232154
Start Date
November 1 2005
End Date
June 1 2006
Last Update
April 21 2011
Active Locations (18)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Alabaster, Alabama, United States, 35007
2
Pfizer Investigational Site
Birmingham, Alabama, United States, 35209
3
Pfizer Investigational Site
Birmingham, Alabama, United States, 35233
4
Pfizer Investigational Site
Birmingham, Alabama, United States, 35242